Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer

This study has been terminated.
(Low patient enrollment; toxicities)
Novartis Pharmaceuticals
Walther Cancer Institute
Information provided by:
Hoosier Cancer Research Network Identifier:
First received: September 12, 2005
Last updated: February 16, 2011
Last verified: February 2011

HER2 gene amplification increases VEGF production in breast cancers; combined inhibition of HER2 and VEGF enhances response in xenograft models. The upregulation of VEGF in HER2-overexpressing breast cancers may contribute to the aggressive phenotype observed in HER2-positive breast cancer. New therapeutics targeting VEGF and/or its receptors may enhance the efficacy of trastuzumab monotherapy.

This trial will investigate the safety and efficacy of combined HER2 and VEGF inhibition.

Condition Intervention Phase
Breast Cancer
Drug: PTK787
Drug: Trastuzumab
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of PTK787 in Combination With Trastuzumab in Patients With Newly Diagnosed HER2 Overexpressing Locally Recurrent or Metastatic Breast Cancer: Hoosier Oncology Group Trial BRE04-80

Resource links provided by NLM:

Further study details as provided by Hoosier Cancer Research Network:

Primary Outcome Measures:
  • Phase I Cohorts: [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
  • The primary objective is to ensure the safety and tolerability of the combination of Trastuzumab and PTK787, [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
  • Phase II Cohorts: [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • To assess response rate of PTK787 combined with trastuzumab in patients with newly diagnosed HER2 overexpressing [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Phase II Cohorts: [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • To assess the safety and tolerability of PTK787 combined with trastuzumab [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • To assess the time to progression and clinical benefit of PTK787 combined with trastuzumab [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: January 2005
Study Completion Date: August 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Trastuzumab + PTK787 for HER2 positive patients
Drug: PTK787
PTK787 daily
Drug: Trastuzumab
Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle*

Detailed Description:

OUTLINE: This is a multi-center study.

PTK787 daily plus trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle.

Patients may continue treatment until disease progression or toxicity intervenes.

Performance Status: ECOG 0 or 1

Life Expectancy: Not specified


  • ANC > 1500 mm3
  • Platelets > 100,000 mm3
  • Hemoglobin > 9 g/dL
  • PTT and INR < 1.5 x ULN


  • ALT and AST < 3 x ULN (< 5 x ULN in patients with known liver metastases)
  • Alkaline phosphatase < 2.5 x ULN
  • Serum bilirubin < 1.5 x ULN


  • Serum creatinine < 1.5 x ULN
  • Proteinuria < 1+ by dipstick OR total urinary protein < 500 mg/24 hours with measured creatinine clearance (CrCl) ≥ 50 mL/min


  • No clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months.
  • LVEF > LLN by MUGA or ECHO (obtained within 28 days prior to being registered for protocol therapy)


  • Not specified

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologic or cytologic diagnosis of breast cancer with evidence of measurable (1) unresectable, locally recurrent, or (2) metastatic disease. Locally recurrent disease must not be amenable to resection OR radiation with curative intent.
  • Patient's disease may not involve more than 3 metastatic sites. In addition, patient may not be symptomatic from pulmonary metastasis or have liver metastasis involving > 50% of parenchyma.
  • HER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry will not be sufficient for entry.
  • Negative pregnancy test

Exclusion Criteria:

  • No prior cytotoxic chemotherapy or trastuzumab for locally recurrent or metastatic disease.
  • No prior treatment with any VEGF inhibiting agents
  • No history or presence of central nervous system (CNS) disease.
  • No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to being registered for protocol therapy.
  • No major surgery within 28 days prior to being registered for protocol therapy.
  • No uncontrolled hypertension (SBP > 170, DBP > 90), history of labile hypertension or history of poor compliance with antihypertensive therapy.
  • No requirement for therapeutic anticoagulation, regular aspirin (> 325 mg/day) or NSAID use.
  • No current breast feeding.
  • No impairment of gastrointestinal (GI) function that may significantly alter the absorption of PTK787.
  • No evidence of other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00216047

United States, Indiana
Elkhart Clinic
Elkhart, Indiana, United States, 46515
Fort Wayne Oncology & Hematology, Inc
Fort Wayne, Indiana, United States, 46815
Center for Cancer Care at Goshen Health System
Goshen, Indiana, United States, 46527
Indiana University Cancer Center
Indianapolis, Indiana, United States, 46202
Arnett Cancer Care
Lafayette, Indiana, United States, 47904
Medical Consultants, P.C.
Muncie, Indiana, United States, 47303
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States, 46601
AP&S Clinic
Terre Haute, Indiana, United States, 47804
Sponsors and Collaborators
Hoosier Cancer Research Network
Novartis Pharmaceuticals
Walther Cancer Institute
Study Chair: Kathy Miller, M.D. Hoosier Oncology Group, LLC
  More Information

Additional Information:
No publications provided

Responsible Party: Kathy Miller, M.D., Hoosier Oncology Group Identifier: NCT00216047     History of Changes
Other Study ID Numbers: HOG BRE04-80
Study First Received: September 12, 2005
Last Updated: February 16, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Hoosier Cancer Research Network:
Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses processed this record on November 25, 2014